

Supplementary Table 2. High-grade 3 (a) and 4 (b) treatment-emergent adverse events in oncolytic virus clinical trials by major routes of administration

<i>Event</i>	<i>Intratumoral</i>	<i>Intravenous</i>	<i>Other Drugs</i>	<i>Total Number</i>
Airway obstruction	1	0	None	1
Anorexia	1	0	None	1
Diarrhea	0	2	None	2
Hyperglycemia	1	0	None	1
Increased uric acid	0	1	None	1
Lymphopenia	1	1	Chemotherapy	2
Neutropenia	1	3	Chemotherapy	4
Optic atrophy	1	0	None	1
Pneumonitis	0	1	Pembrolizumab	1
Pulmonary embolism	2	0	None	2
Seizure	0	1	None	1
Sepsis	0	1	Chemotherapy	1
Thrombocytopenia	3	0	Chemotherapy Targeted Therapy	3

Supplementary Table 3. High-grade 3 (a) and 4 (b) treatment-emergent adverse events in oncolytic virus clinical trials by major routes of administration

<i>Event</i>	<i>Intratumoral</i>		<i>Intravenous</i>		<i>Total</i>
	<i>N</i>	<i>Other Drugs</i>	<i>N</i>	<i>Other Drugs</i>	
Anemia	1	None	3	Chemotherapy	4
Anorexia	0	n/a	1	None	1
Aseptic meningitis	0	n/a	1	None	1
Cellulitis	1	None	0	n/a	1
DVT	1	None	0	n/a	1
Dehydration	1	Ipilimumab	0	n/a	1
Diarrhea	3	Ipilimumab ¹	1	Chemotherapy	4
Dyspnea	2	None	1	None	3
Fatigue	3	Ipilimumab ¹	5	Chemotherapy ¹	8
Febrile neutropenia	0	n/a	1	Chemotherapy	1
Fever	4	Ipilimumab ¹	4	Chemotherapy ¹	8
Flu-like symptoms	1	Ipilimumab ¹	1	None	2
Hepatitis	0	n/a	1	Pembrolizumab	1
Hyperglycemia	1	None	0	n/a	1
Hypoglycemia	2	None	0	n/a	2
Hypokalemia	1	None	0	n/a	1
Hyponatremia	1	None	1	None	2
Hypophosphatemia	1	None	1	None	2
Hypotension	0	n/a	2	Chemotherapy ¹	2
Increased LFTs	1	Pro-drug	2	Chemotherapy ¹	3
Infection	1	None	0	n/a	1
Infusion reaction	0	n/a	1	None	1
Leukopenia	3	None	6	Chemotherapy ²	9
Myalgias	0	n/a	1	Chemotherapy	1
Nausea	1	Ipilimumab ¹	4	Chemotherapy ³	5
Neutropenia	0	n/a	7	Chemotherapy ⁴	7
Pain	5	None	2	Chemotherapy ¹	7
Pneumothorax	0	n/a	1	None	1
Prolonged PT	1	Pro-drug and radiation	1	None	2
Respiratory distress	0	n/a	1	Chemotherapy	1
Seizure	0	n/a	1	None	1
Thrombocytopenia	0	n/a	6	Chemotherapy ⁵	6
Tumor lysis syndrome	1	Pro-drug	0	n/a	1
Urinary frequency	1	5-FC, valganciclovir, radiation	0	n/a	1
Urinary retention	1	None	0	n/a	1
Vomiting	2	Ipilimumab ¹	2	Chemotherapy ³	4

¹Used in one patient; ²Used in four patients; ³Used in two patients; ⁴Used in five patients; ⁵Used in three patients; Abbreviations: DVT, deep venous thrombosis; LFTs, liver function tests; n/a, not applicable; PT, prothrombin time; 5-FC, 5-fluorocytosine.